Incidence Of Hepatitis In Intensive Care Unit

Intensive Care Unit Clinical Trial

Official title:

Incidence Of Hepatitis And Its Effect On Prognosis In Patients Who Follow In Intensive Care Unit

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03456037
• Other study ID #: hepatitis
• Status: Recruiting
• Phase: N/A
• First received: February 28, 2018
• Last updated: March 6, 2018
• Start date: April 1, 2018
• Est. completion date: July 1, 2019

Study information

• Verified date: March 2018
• Source: Sakarya University
• Contact: Havva Sayhan,, Assis Prof
• Phone: +905056621021
• Email: hsayhan[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim is to investigate incidence of HBsAg, anti-HCV in serum samples and evaluation of biomarkers taken from patients who were followed the intensive care unit of Sakarya University Training and Research Hospital and The intensive care unit attracts attention by making health workers more susceptible to the risk of hepatitis.

Description:

This retrospective study included 536 cases who were followed with various diagnoses in intensive care units between 1 Ocak 2015 ile 1 Ocak 2016, covering the six months period, retrospectively. Sakarya University's Faculty of Medicine Review Board (71522473/050.01.04/113) approved the study after approval of the research ethics committee (. Medical record forms and electronic medical record system of the hospital were used in the analysis of medical data with regard to age, sex, HBsAg, anti-HCV, AST, ALT, bilirubin, creatinine levels.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: July 1, 2019
• Est. primary completion date: May 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

Inclusion Criteria:

All patients who were followed in the intensive care unit

Exclusion Criteria:

Related Conditions & MeSH terms

• Intensive Care Unit

Intervention

Other:
• hepatitis viruses
There are 5 main hepatitis viruses, referred to as types A, B, C, D and E. These 5 types are of greatest concern because of the burden of illness and death they cause and the potential for outbreaks and epidemic spread. In particular, types B and C lead to chronic disease in hundreds of millions of people and, together, are the most common cause of liver cirrhosis and cancer.The aim is to investigate incidence of HBsAg, anti-HCV in serum samples and evaluation of biomarkers taken from patients who were followed the intensive care unit of Sakarya University Training and Research Hospital.

Locations

Country	Name	City	State
Turkey	Sakarya University Research and Training Hospital	Sakarya

Sponsors (1)

Lead Sponsor	Collaborator
Sakarya University

Country where clinical trial is conducted

Turkey, 

References & Publications (1)

Dayan S, Tekin A, Tekin R, Dal T, Hosoglu S, Yazgan UC, Bekçibasi M, Gül K. HBsAg, anti-HCV, anti-HIV 1/2 and syphilis seroprevalence in healthy volunteer blood donors in southeastern Anatolia. J Infect Dev Ctries. 2013 Sep 16;7(9):665-9. doi: 10.3855/jid — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HBsAg	HBsAg is the serologic hallmark of HBV infection and is the first marker to appear after acute infection.	1 month
Secondary	anti-HCV	Anti-HCV antibody tests look for antibodies to HCV in the blood, indicating an HCV infection has occurred.	1mounth